Muskiet MHA, et al. - In type 2 diabetes (T2DM) patients, researchers compared the impacts of long-term treatment with the glucagon-like peptide-1 receptor agonist exenatide twice-daily vs titrated insulin glargine (iGlar) on renal function and albuminuria. Participants in this post-hoc analysis were 54 overweight T2DM patients. Study participants were randomised to exenatide 10 µg twice-daily or titrated iGlar on-top-of metformin for 52-weeks. Among T2DM patients with no overt nephropathy, twice daily exenatide one-year treatment does not influence renal function-decline or onset/progression of albuminuria compared to titrated iGlar.